NASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis $8.33 -0.33 (-3.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.33▼$8.7050-Day Range$8.29▼$9.2952-Week Range$4.35▼$9.60Volume5,588 shsAverage Volume7,671 shsMarket Capitalization$15.18 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Talis Biomedical alerts: Email Address Talis Biomedical MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside40.0% Downside$5.00 Price TargetShort InterestHealthy0.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.43 out of 5 starsMedical Sector899th out of 936 stocksAnalytical Instruments Industry26th out of 27 stocks 0.5 Analyst's Opinion Consensus RatingTalis Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTalis Biomedical has received no research coverage in the past 90 days.Read more about Talis Biomedical's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.84% of the float of Talis Biomedical has been sold short.Short Interest Ratio / Days to CoverTalis Biomedical has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Talis Biomedical has recently decreased by 4.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTalis Biomedical does not currently pay a dividend.Dividend GrowthTalis Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLIS. Previous Next 2.0 News and Social Media Coverage News SentimentTalis Biomedical has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Talis Biomedical this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Talis Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders46.00% of the stock of Talis Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.77% of the stock of Talis Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Talis Biomedical's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Talis Biomedical is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Talis Biomedical is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTalis Biomedical has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Talis Biomedical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Talis Biomedical Stock (NASDAQ:TLIS)Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.Read More TLIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLIS Stock News HeadlinesJuly 24 at 4:36 AM | americanbankingnews.comTalis Biomedical (NASDAQ:TLIS) Shares Down 0.2% July 21, 2024 | americanbankingnews.comPrenetics Global (NASDAQ:PRE) vs. Talis Biomedical (NASDAQ:TLIS) Head to Head SurveyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 10, 2024 | investing.comTalis Biomedical Corp (TLIS)May 8, 2024 | investorplace.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024March 31, 2024 | finance.yahoo.comTalis Biomedical Corporation (TLIS)February 16, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical CorporationFebruary 15, 2024 | finance.yahoo.comTLIS Feb 2024 2.500 putJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.November 14, 2023 | bizjournals.comPeninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'November 14, 2023 | finanznachrichten.deTalis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashNovember 14, 2023 | msn.comLICY, BTAI and HROW among mid-day moversNovember 14, 2023 | msn.comTalis reviewing strategic alternatives, stock rallies 35%November 14, 2023 | msn.comWhy Talis Biomedical (TLIS) Stock Is Exploding HigherNovember 14, 2023 | finance.yahoo.comTalis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashAugust 16, 2023 | msn.comBTIG Maintains Talis Biomedical (TLIS) Sell RecommendationAugust 16, 2023 | markets.businessinsider.comBTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To KnowAugust 11, 2023 | finance.yahoo.comTalis Biomedical Announces Second Quarter 2023 Financial Results and Business UpdateSee More Headlines Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TLIS CUSIPN/A CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees99Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside-40.0%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($31.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,010,000.00 Net Margins-5,784.73% Pretax Margin-5,784.73% Return on Equity-75.40% Return on Assets-56.16% Debt Debt-to-Equity RatioN/A Current Ratio7.51 Quick Ratio7.51 Sales & Book Value Annual Sales$348,000.00 Price / Sales43.61 Cash FlowN/A Price / Cash FlowN/A Book Value$37.95 per share Price / Book0.22Miscellaneous Outstanding Shares1,822,000Free Float984,000Market Cap$15.18 million OptionableNo Data Beta1.68 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Robert Kelley MBA (Age 52)CEO & Director Comp: $852.36kDr. Andrew A. Lukowiak Ph.D. (Age 51)President & Chief Scientific Officer Comp: $904.9kDr. Rustem F. Ismagilov Ph.D. (Age 50)Co-Founder & Director Comp: $53.95kMs. Rebecca Markovich (Age 50)Interim Chief Financial Officer Comp: $379.23kMr. Liang Li Ph.D.Co-Founder and Director of Technology & StrategyMs. Emily FaucetteSenior Vice President of Corporate Communications & Investor RelationsMs. Jill GreenSenior Vice President of LegalMr. Matthew PepeVice President of Human ResourceMs. Margaret Barrett M.S.ControllerGillian GreenCompany SecretaryMore ExecutivesKey CompetitorsLucid DiagnosticsNASDAQ:LUCDPrenetics GlobalNASDAQ:PREBionano GenomicsNASDAQ:BNGOAccelerate DiagnosticsNASDAQ:AXDXRapid Micro BiosystemsNASDAQ:RPIDView All Competitors TLIS Stock Analysis - Frequently Asked Questions How have TLIS shares performed this year? Talis Biomedical's stock was trading at $7.45 at the start of the year. Since then, TLIS stock has increased by 11.8% and is now trading at $8.33. View the best growth stocks for 2024 here. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($7.15) earnings per share (EPS) for the quarter. The business earned $0.07 million during the quarter. Talis Biomedical had a negative net margin of 5,784.73% and a negative trailing twelve-month return on equity of 75.40%. When did Talis Biomedical's stock split? Talis Biomedical shares reverse split on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLIS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
